Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib

BACKGROUND: Multimodality treatment of gastrointestinal stromal tumor (GIST) with surgery and adjuvant imatinib mesylate (IM), along with an emerging role for neoadjuvant IM prior to evaluation for resectability has resulted in high survival rates. METHODS: We conducted a retrospective analysis of p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Main Authors: Ramaswamy, Anant, Jain, Deepak, Sahu, Arvind, Ghosh, Joydeep, Prasad, Priya, Deodhar, Kedar, Shetty, Nitin, Banavali, Shripad, Shrikhande, Shailesh, Ostwal, Vikas
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963379/
https://ncbi.nlm.nih.gov/pubmed/27563454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.13
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados